Zai Lab (ZLABN) AI Stock Analysis

Company Guidance

Management guided to both near‑term commercial stabilization and a fast, metric‑driven clinical cadence: commercially, Q2 net product revenue rose 11% sequentially to $105.8 million, the business remained commercially profitable, cash was $717.5 million at quarter‑end, operating expenses are expected to be broadly stable through the remainder of the year, they expect to stabilize product sales in H2 2026 and return to meaningful year‑over‑year growth in 2027 with a potential first U.S. product launch in 2028 (and targeted NRDL actions such as KarXT and VYVGART around 2027); clinically, they expect three registrational programs in SCLC and neuroendocrine carcinoma by year‑end 2026, Zoci’s global Phase III to complete enrollment in H1 2027 with a U.S. accelerated approval submission later in 2027 and approval anticipated in 2028, ~60 patients (median follow‑up ~8–9 months) to be presented at ESMO in October, dose exploration at 1.2 and 1.6 mg/kg with 1.6 mg/kg the planned RP2D, and a goal of materially improving on the current ~60–70% response/≈5‑month median PFS benchmark (targeting ~80% response and ~50% PFS improvement); immunology and earlier‑stage timelines include ZL‑1503 SAD/healthy‑volunteer PK/PD and ADA data in H2 2026 (biomarkers pSTAT6, TARC, CCL26), MAD AD data at a major conference next year, ZL‑6201 initial data in H1 2027, and an IND for ZL‑1311 by year‑end 2026, all underpinned by disciplined capital allocation and the claim that Zoci moved from IND to global pivotal in <2 years.